Rallybio Co. (NASDAQ: RLYB) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up [Yahoo! Finance]
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at Wedbush from $13.00 to $11.00. They now have an "outperform" rating on the stock.
Rallybio shares gain on investment from J&J for rare fetal condition treatment [Seeking Alpha]